Latest news
{{'2026-04-23T09:10:04Z' | dateFormatFilter}}
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
{{'2026-04-20T09:19:50Z' | dateFormatFilter}}
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
{{'2026-04-14T06:00:00Z' | dateFormatFilter}}
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
